Predicting survival in malignant mesothelioma

Musk, Aw Bill; Olsen, Nola; Alfonso, Helman; Reid, Alison; Mina, Rob; Franklin, Peter; Sleith, Jan; Hammond, Neel; Threlfall, Tim; Shilkin, K. B.; Klerk, Nicholas de

doi:10.1183/09031936.00000811

Cited by 104 publications

(68 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, expertise in palliative care has certainly increased over the past decade. Also, tumours may be diagnosed earlier [10] due to wider knowledge of the effects of asbestos exposure, a less pessimistic view on the clinical management of mesothelioma patients or to better prospects for financial compensation after confirmation of the diagnosis [18].…”

Section: Discussionmentioning

confidence: 99%

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Damhuis¹,

Schroten²,

Burgers³

2011

Eur Respir J

View full text Add to dashboard Cite

Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment. Chemotherapy with cisplatin-antifolate combinations recently showed promising response rates and prolonged survival in randomised trials.To assess the impact of this development on clinical practice and survival at a population-based level, treatment patterns and survival trends were studied for patients diagnosed with mesothelioma in the period 1995-2006. 4,731 records were retrieved from the Netherlands Cancer Registry and chemotherapy use and median survival were analysed.For the periods 1995-1998 to 2005-2006, chemotherapy use increased from 8% to 36%. Median survival increased over time from 7.1 months to 9.2 months. For pleural mesothelioma, multivariable analysis demonstrated that survival was poorer for elderly patients and sarcomatoid tumours. The prognostic impact of chemotherapy increased with time. Median survival for chemotherapy treated patients improved from 10.1 months (1995-1998) to 13.1 months (2005)(2006). For peritoneal mesothelioma, median survival was poor (3.9 months) but better for females and younger patients.This study demonstrates that chemotherapy use increased at a national level and coincided with an improvement in survival. The novel chemotherapy regimen appears to be more effective but, due to the observational nature of this study, alternative explanations cannot be excluded.

show abstract

Section: Discussionmentioning

confidence: 99%

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Damhuis¹,

Schroten²,

Burgers³

2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…These patients should be considered for systemic therapy. Even with treatment, MPM has a poor prognosis with median survival of approximately one-year and cure is very rare (33)(34)(35). The limited efficacy of therapy for MPM highlights the need to develop more effective therapies for MPM which is challenged by the heterogeneity of MPM (with three pathological subtypes), the relatively low incidence of the disease, and the degree of difficulty with assessment of response.…”

Section: Introductionmentioning

confidence: 99%

Novel systemic therapy against malignant pleural mesothelioma

Mancuso

Neal

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum analog, an anti-metabolite, and sometimes anti-angiogenic therapy, but there is currently no well-established standard therapy for refractory or relapsed disease. This review focuses on efforts to develop improved systemic therapy for the treatment of malignant pleural mesothelioma (MPM) including cytotoxic systemic therapy, a variety of tyrosine kinase inhibitors and their downstream effector pathways, pharmacologic targeting of the epigenome, novel approaches to target proteins expressed on mesothelioma cells (such as mesothelin), arginine depletion therapy, and the emerging role of immunotherapy. Overall, these studies demonstrate the challenges of improving systemic therapy for MPM and highlight the need to develop therapeutic strategies to control this disease.

show abstract

“…These findings are consistent with previously published data. 55,56 However, a comprehensive understanding of the survival differences between these groups would require more detailed information on clinical stage at diagnosis and patient performance status.…”

mentioning

confidence: 99%

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Soeberg

Creighton

Currow

et al. 2016

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Introduction: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types. Methods:We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972Australia, -2009. We also calculated 5-year relative survival for people diagnosed 1972-2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories.Results: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age-standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five-year relative survival remained stable for MPM and MPeM. However, 5-year relative survival in 2002-2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% .2%]) compared to all other non-epithelioid histological subtypes (6.9% [95%CI 5.0-9.1%]), a 70% difference. Survival was also greater for women with .4%]) compared to men (7.0% [95%CI 5.1-9.2%]).Interpretation: MPM incidence rates have stabilised since the mid-1990s, suggesting that maximum incidence levels have been reached. When more up-to-date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.

show abstract

Predicting survival in malignant mesothelioma

Cited by 104 publications

References 32 publications

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Novel systemic therapy against malignant pleural mesothelioma

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Contact Info

Product

Resources

About